Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Cosmos Health reported preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, and reaffirmed full-year revenue guidance above $90 million, up approximately 38%; it expects fourth-quarter revenue of at least $35.7 million, up approximately 81% year over year. The company said U.S. e-commerce has 8,940 active subscriptions as of October 19 and expects that business to generate approximately $15 million in revenue and $10.5 million in gross profit in Q4. It also cited more than 5.1 million shares repurchased for approximately $1.1 million and set 2029 targets of $200.6 million revenue, $71.2 million gross profit and $44.2 million adjusted EBITDA.

Analysis

The key issue is conversion, not headline growth. The projected fourth-quarter e-commerce revenue and gross profit imply unusually high gross-profit contribution; verify reported revenue recognition, product mix, fulfillment costs, subscription retention and customer-acquisition spending before extrapolating it. A five-day subscription jump may reflect a campaign or definition change rather than durable recurring demand. Likewise, Cana’s unit pipeline is not equivalent to orders, recognized revenue or profitable capacity utilization.

Near term, the shareholder letter can support momentum, but the next hard catalyst is reported results that reconcile the preliminary outlook with cash generation. Over 1–3 months, watch e-commerce cohort retention, gross margin and cash conversion, plus whether contract-manufacturing pipeline converts into customer orders. Over 6–18 months, the self-funding objective and 2029 adjusted EBITDA path require evidence that operating costs and working capital do not absorb growth. Non-core assets are not cash until monetized; buybacks should be assessed against liquidity and any share issuance, not treated as proof of undervaluation.

Contrarian read: the release offers a compelling growth narrative, but the market may be underweighting execution and financing risk. A miss against the fourth-quarter outlook or weak cash conversion could unwind optimism quickly; confirmed recurring sales and improving cash generation would make the growth case more credible. No valuation or liquidity data are supplied, so a price target or confident directional bet is not justified.

Key Decisions for Investors

• Do not chase COSM solely on the shareholder letter. Treat the outlook as company guidance pending reported results and reconciliation to filings.
• Set an event-driven watch: consider a long only after reported revenue tracks the outlook and filings corroborate e-commerce gross profit, subscription retention and cash conversion. Keep exposure modest until those measures are verified.
• Monitor the next results for contract-manufacturing pipeline conversion into orders and recognized revenue, alongside working-capital needs. Pipeline units alone are not a revenue catalyst.
• Falsification: a material shortfall from the company’s fourth-quarter outlook, deteriorating e-commerce retention or gross margin, rising working-capital strain, or renewed share issuance would undermine the bullish thesis. Verify repurchase and non-core-asset details before assigning them balance-sheet value.